RESUMEN
Modern literature on the physical property of the-source point were collected from Chinese National Knowledge Infrastructure(CNKI) and China Biology Medicine(CBM) databases. The physical property,relevant diseases and-source acupoints were analyzed through statistical analysis of literature metrology. It is considered that articles on the electrical resistance of acupoint account for the largest part,which are mainly related to hyperthyreosis and the change of menstrual cycle. The second part is radiation spectrum,which are mostly relevant to the coronary heart disease and then the physiological change of healthy people. As to the diseases,articles of cardiovascular diseases are taken the most proportion,which were treated with the 12-source points,Shenmen(HT 7) and Daling(PC 7). Also,the results present the physical property of-source acupoints in themeridians is more sensitive to diseases and the physical property is specific to diseases. Besides,the-source acupoint can show the pathological changes of its own meridian.
RESUMEN
Acupoint catgut embedding (ACE) was applied widely to antiweight in China. The aim of this review is to estimate the effectiveness and safety of ACE on obesity. A literature search was conducted in PubMed, Cochrane Library, EBASE, CNKI, and so forth, using combination subject terms of obesity (or overweight, weight loss, etc.) and acupoint catgut embedding (or catgut implantation, catgut embedding). Improvement rate, reduction of body weight and body mass index (BMI), and so forth were analyzed. 43 studies were included for systematic review and meta-analysis. Although with poor methodological quality, ACE was superior to manual acupuncture (MA), sham, and cupping in improvement rate and presented a better tendency (OR > 1) compared with drugs and electroacupuncture (EA). Mean values of weight loss by ACE were 1.14 kg, 1.26 kg, 1.79 kg, and 3.01 kg comparing with MA, drugs, EA, and sham, respectively. Mean of BMI reduced to 0.56 kg/m(2), 0.83 kg/m(2), 0.79 kg/m(2), and 1.63 kg/m(2) comparing with MA, drugs, EA, and sham. Less adverse effects were reported. Pooled outcomes presented a tendency of equal or superior effects to other interventions and fewer side effects. Future high quality trials with rigorous design and positive FDA approved drug as control are urgent to assess the effect of ACE for obesity. PROSPERO registration number is as follows: CRD42015016006.